- Chemical Name:Tyrosine, beta-methyl-
- CAS No.:59-25-6
- Molecular Formula:C10H13NO3
- Molecular Weight:195.218
- Hs Code.:
- Nikkaji Number:J303.820C
- Mol file:59-25-6.mol
Synonyms:beta-methyltyrosine;beta-MeTyr
Synonyms:beta-methyltyrosine;beta-MeTyr
98%min *data from raw suppliers
There total 2 articles about Tyrosine, beta-methyl- which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:
Reference yield:
Reference yield:
The research focuses on the design, synthesis, and preliminary biological evaluation of acridine compounds for a combined targeted chemo-radionuclide therapy approach to treat melanoma. The study exploits the structural similarity of these compounds to benzamides, which are known to have a specific affinity for melanin. The experiments involved the preparation of iodo-acridone and acridine carboxamides, which were evaluated for their in vitro cytotoxic properties and then radioiodinated with [125I]NaI for high specific activity. Biodistribution studies in B16F0 murine melanoma tumor-bearing mice were conducted to assess the tumor concentrations and in vivo kinetic profiles of the compounds. The main reactants used in the synthesis include various iodo-acridone and acridine carboxamide derivatives, along with reagents like [125I]NaI for radioiodination. Analyses included cytotoxicity assays, partition coefficient measurements, in vitro binding to melanin, and in vivo biodistribution studies to evaluate the compounds' affinity for melanoma tumors and their elimination rates. The research aimed to identify lead candidates for use in radionuclide therapy and/or chemotherapy of melanoma, with a focus on compounds that demonstrated high, long-lasting tumor concentrations and favorable kinetic profiles for targeted radionuclide therapy.